PortfoliosLab logoPortfoliosLab logo
AXSM vs. NVO
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

AXSM vs. NVO - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Axsome Therapeutics, Inc. (AXSM) and Novo Nordisk A/S (NVO). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, AXSM achieves a 32.48% return, which is significantly higher than NVO's -3.54% return. Over the past 10 years, AXSM has outperformed NVO with an annualized return of 42.31%, while NVO has yielded a comparatively lower 8.62% annualized return.


AXSM

1D
-2.37%
1M
2.54%
YTD
32.48%
6M
56.93%
1Y
138.04%
3Y*
40.04%
5Y*
27.97%
10Y*
42.31%

NVO

1D
3.36%
1M
5.47%
YTD
-3.54%
6M
-4.91%
1Y
-28.81%
3Y*
-13.64%
5Y*
5.10%
10Y*
8.62%
*Multi-year figures are annualized to reflect compound growth (CAGR)

AXSM vs. NVO - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
AXSM
Axsome Therapeutics, Inc.
32.48%115.86%6.31%3.19%104.16%-53.63%-21.18%3,565.25%-49.64%-17.04%
NVO
Novo Nordisk A/S
-3.54%-39.22%-15.93%54.84%22.66%63.52%23.33%28.70%-12.98%52.92%

Correlation

The correlation between AXSM and NVO is 0.17, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.17

Correlation (3Y)
Calculated over the trailing 3-year period

0.16

Correlation (5Y)
Calculated over the trailing 5-year period

0.18

Correlation (10Y)
Calculated over the trailing 10-year period

0.15

Correlation (All Time)
Calculated using the full available price history since Nov 19, 2015

0.15

Fundamentals

Market Cap

AXSM:

$12.39B

NVO:

$210.96B

EPS

AXSM:

-$3.74

NVO:

DKK 27.42

PS Ratio

AXSM:

17.19

NVO:

4.21

PB Ratio

AXSM:

226.95

NVO:

6.80

Total Revenue (TTM)

AXSM:

$708.24M

NVO:

DKK 327.80B

Gross Profit (TTM)

AXSM:

$655.82M

NVO:

DKK 268.30B

EBITDA (TTM)

AXSM:

-$172.72M

NVO:

DKK 181.54B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

AXSM vs. NVO — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

AXSM
AXSM Risk / Return Rank: 9696
Overall Rank
AXSM Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
AXSM Sortino Ratio Rank: 9797
Sortino Ratio Rank
AXSM Omega Ratio Rank: 9595
Omega Ratio Rank
AXSM Calmar Ratio Rank: 9696
Calmar Ratio Rank
AXSM Martin Ratio Rank: 9696
Martin Ratio Rank

NVO
NVO Risk / Return Rank: 2020
Overall Rank
NVO Sharpe Ratio Rank: 1818
Sharpe Ratio Rank
NVO Sortino Ratio Rank: 2121
Sortino Ratio Rank
NVO Omega Ratio Rank: 1919
Omega Ratio Rank
NVO Calmar Ratio Rank: 2121
Calmar Ratio Rank
NVO Martin Ratio Rank: 2323
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

AXSM vs. NVO - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Axsome Therapeutics, Inc. (AXSM) and Novo Nordisk A/S (NVO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


AXSMNVODifference
Sharpe ratioReturn per unit of total volatility

+3.88

Sortino ratioReturn per unit of downside risk

+5.20

Omega ratioGain probability vs. loss probability

1.57

0.93

+0.64

Calmar ratioReturn relative to maximum drawdown

7.51

-0.59

+8.09

Martin ratioReturn relative to average drawdown

22.08

-0.93

+23.02

AXSM vs. NVO - Sharpe Ratio Comparison

The current AXSM Sharpe Ratio is 3.33, which is higher than the NVO Sharpe Ratio of -0.56. The chart below compares the historical Sharpe Ratios of AXSM and NVO, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

AXSM vs. NVO - Drawdown Comparison

The maximum AXSM drawdown since its inception was -86.65%, which is greater than NVO's maximum drawdown of -74.70%. Use the drawdown chart below to compare losses from any high point for AXSM and NVO.


Loading charts...

Drawdown Indicators


AXSMNVODifference

Max Drawdown

Largest peak-to-trough decline

-86.65%

-74.70%

-11.95%

Max Drawdown (1Y)

Largest decline over 1 year

-18.50%

-49.17%

+30.67%

Max Drawdown (3Y)

Largest decline over 3 years

-34.83%

-74.70%

+39.87%

Max Drawdown (5Y)

Largest decline over 5 years

-72.91%

-74.70%

+1.79%

Max Drawdown (10Y)

Largest decline over 10 years

-81.26%

-74.70%

-6.56%

Current Drawdown

Current decline from peak

-5.17%

-65.54%

+60.37%

Average Drawdown

Average peak-to-trough decline

-39.39%

-17.81%

-21.58%

Ulcer Index

Depth and duration of drawdowns from previous peaks

6.28%

30.87%

-24.59%

Volatility

AXSM vs. NVO - Volatility Comparison

The current volatility for Axsome Therapeutics, Inc. (AXSM) is 9.26%, while Novo Nordisk A/S (NVO) has a volatility of 12.04%. This indicates that AXSM experiences smaller price fluctuations and is considered to be less risky than NVO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


AXSMNVODifference

Volatility (1M)

Calculated over the trailing 1-month period

9.26%

12.04%

-2.78%

Volatility (6M)

Calculated over the trailing 6-month period

33.26%

38.41%

-5.15%

Volatility (1Y)

Calculated over the trailing 1-year period

41.75%

52.06%

-10.31%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

70.26%

38.48%

+31.78%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

90.40%

32.58%

+57.82%

Dividends

AXSM vs. NVO - Dividend Comparison

AXSM has not paid dividends to shareholders, while NVO's dividend yield for the trailing twelve months is around 3.80%.


PositionTTM20252024202320222021202020192018201720162015
AXSM
Axsome Therapeutics, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
NVO
Novo Nordisk A/S
3.80%3.31%1.68%1.00%1.20%1.35%1.87%2.14%1.45%1.52%2.87%0.92%

Financials

AXSM vs. NVO - Financials Comparison

This section allows you to compare key financial metrics between Axsome Therapeutics, Inc. and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.0020.00B40.00B60.00B80.00B100.00B20222023202420252026
191.20M
96.82B
(AXSM) Total Revenue
(NVO) Total Revenue
Please note, different currencies. AXSM values in USD, NVO values in DKK

AXSM vs. NVO - Profitability Comparison

The chart below illustrates the profitability comparison between Axsome Therapeutics, Inc. and Novo Nordisk A/S over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

80.0%85.0%90.0%20222023202420252026
92.3%
86.0%
Portfolio components
AXSM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported a gross profit of 176.48M and revenue of 191.20M. Therefore, the gross margin over that period was 92.3%.

NVO - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a gross profit of 83.23B and revenue of 96.82B. Therefore, the gross margin over that period was 86.0%.

AXSM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported an operating income of -63.36M and revenue of 191.20M, resulting in an operating margin of -33.1%.

NVO - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported an operating income of 59.62B and revenue of 96.82B, resulting in an operating margin of 61.6%.

AXSM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Axsome Therapeutics, Inc. reported a net income of -64.54M and revenue of 191.20M, resulting in a net margin of -33.8%.

NVO - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Novo Nordisk A/S reported a net income of 48.56B and revenue of 96.82B, resulting in a net margin of 50.2%.


Frequently Asked Questions


AXSM and NVO have a correlation of 0.17, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

NVO has higher volatility (12.04%) compared to AXSM (9.26%). In terms of maximum drawdown, AXSM dropped -86.65% vs NVO's -74.70%.

AXSM currently has the higher Sharpe Ratio (3.33 vs -0.56), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for AXSM and NVO

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer